Clinical trial
DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C…
NCT00233649 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00233649 |
|---|---|
| Title | DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines |
| Official title | DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Diabetes Mellitus Type 2, Crestor, Rosuvastatin, LDL Cholesterol, Observational |
| Enrollment | 2,500 |
| Start date | May 1, 2004 |
| First posted | Oct 6, 2005 |
| Last update posted | Nov 19, 2010 |
| Countries | Netherlands |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: